S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

First International Summit on Interventional Pharmacoeconomics

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Jan

Today In Oncology

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Locoregionally Advanced Nasopharyngeal Carcinoma: Comparison of Regimens Following Induction Chemotherapy

Bacterial Decolonization to Manage Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma

Lifileucel Demonstrates Feasibility and Disease Stability in Advanced Head and Neck Squamous Cell Carcinoma

New Liquid Biopsy Test for Early Detection of Head and Neck Cancers

Chronic Toxicity Rates With De-escalated vs Standard Adjuvant Radiotherapy in HPV-Associated Oropharyngeal Squamous Cell Carcinoma